LT3057969T - Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit - Google Patents
Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kitInfo
- Publication number
- LT3057969T LT3057969T LTEP14799576.5T LT14799576T LT3057969T LT 3057969 T LT3057969 T LT 3057969T LT 14799576 T LT14799576 T LT 14799576T LT 3057969 T LT3057969 T LT 3057969T
- Authority
- LT
- Lithuania
- Prior art keywords
- kit
- compositions useful
- disorders related
- treating disorders
- treating
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Jellies, Jams, And Syrups (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892086P | 2013-10-17 | 2013-10-17 | |
| US201461931204P | 2014-01-24 | 2014-01-24 | |
| US201461975229P | 2014-04-04 | 2014-04-04 | |
| PCT/US2014/060746 WO2015057873A1 (en) | 2013-10-17 | 2014-10-15 | Compositions useful for treating disorders related to kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3057969T true LT3057969T (lt) | 2018-07-10 |
Family
ID=51904226
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP14799576.5T LT3057969T (lt) | 2013-10-17 | 2014-10-15 | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit |
| LTPA2021003C LTC3057969I2 (lt) | 2013-10-17 | 2021-03-16 | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTPA2021003C LTC3057969I2 (lt) | 2013-10-17 | 2021-03-16 | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US9200002B2 (enExample) |
| EP (2) | EP3057969B1 (enExample) |
| JP (2) | JP6446040B2 (enExample) |
| KR (1) | KR102378689B1 (enExample) |
| CN (2) | CN110003217B (enExample) |
| AU (1) | AU2014337314B2 (enExample) |
| BR (1) | BR112016008541B1 (enExample) |
| CA (1) | CA2926999C (enExample) |
| CY (2) | CY1121182T1 (enExample) |
| DK (1) | DK3057969T3 (enExample) |
| ES (2) | ES2683127T3 (enExample) |
| HR (1) | HRP20181388T1 (enExample) |
| HU (3) | HUE059041T2 (enExample) |
| IL (1) | IL244677B (enExample) |
| LT (2) | LT3057969T (enExample) |
| MX (1) | MX365614B (enExample) |
| NL (1) | NL301094I2 (enExample) |
| NO (1) | NO2021012I1 (enExample) |
| PH (1) | PH12016500611A1 (enExample) |
| PL (2) | PL3409674T3 (enExample) |
| PT (2) | PT3057969T (enExample) |
| RS (1) | RS57542B1 (enExample) |
| RU (1) | RU2706235C2 (enExample) |
| SG (1) | SG11201602937UA (enExample) |
| SI (1) | SI3057969T1 (enExample) |
| SM (1) | SMT201800448T1 (enExample) |
| TW (1) | TWI683814B (enExample) |
| UY (1) | UY35787A (enExample) |
| WO (1) | WO2015057873A1 (enExample) |
| ZA (1) | ZA201601970B (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| BR112015000653A2 (pt) | 2012-07-11 | 2019-11-05 | Blueprint Medicines Corp | compostos inibidores do receptor de fator de crescimento de fibroblasto, sua composição farmacêutica e seus usos |
| NZ711376A (en) | 2013-03-15 | 2020-01-31 | Sanofi Sa | Heteroaryl compounds and uses thereof |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| AU2014228746B2 (en) | 2013-03-15 | 2018-08-30 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| FR3008779B1 (fr) | 2013-07-19 | 2018-01-26 | Areva Np | Barre antivibratoire pour faisceau de tubes d'un generateur de vapeur |
| RS57542B1 (sr) | 2013-10-17 | 2018-10-31 | Blueprint Medicines Corp | Kompozicije korisne za lečenje poremećaja povezanih sa kit-om |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| DK3395814T3 (da) | 2013-10-25 | 2022-07-04 | Blueprint Medicines Corp | Hæmmere af fibroblastvækstfaktorreceptoren |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| US9944664B2 (en) * | 2014-04-15 | 2018-04-17 | Dow Agrosciences Llc | Metalloenzyme inhibitor compounds as fungicides |
| WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| WO2017004134A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| JP6816100B2 (ja) | 2015-07-16 | 2021-01-20 | アレイ バイオファーマ、インコーポレイテッド | ＲＥＴキナーゼ阻害物質としての置換ピラゾロ［１，５−ａ］ピリジン化合物 |
| JP2018521076A (ja) | 2015-07-24 | 2018-08-02 | ブループリント メディシンズ コーポレイション | Ｋｉｔ及びｐｄｇｆｒに関連する疾病を治療するのに有用な化合物 |
| CA2995997A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| US10724102B2 (en) | 2015-10-26 | 2020-07-28 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
| TWI787018B (zh) | 2015-11-02 | 2022-12-11 | 美商纜圖藥品公司 | 轉染過程重排之抑制劑 |
| KR20180081790A (ko) | 2015-11-19 | 2018-07-17 | 블루프린트 메디신즈 코포레이션 | Ntrk 관련 장애의 치료에 유용한 화합물 및 조성물 |
| UY37155A (es) | 2016-03-17 | 2017-10-31 | Blueprint Medicines Corp | Inhibidores de ret |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| PL3439663T3 (pl) | 2016-04-04 | 2024-11-18 | Loxo Oncology, Inc. | Sposoby leczenia nowotworów wieku dziecięcego |
| SG11201808559PA (en) | 2016-04-04 | 2018-10-30 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| FI3442977T3 (fi) * | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
| FI3800189T3 (fi) | 2016-05-18 | 2023-07-31 | Loxo Oncology Inc | (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin valmistaminen |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| US10035789B2 (en) * | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| ES2948194T3 (es) | 2017-01-18 | 2023-09-01 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2018183712A1 (en) * | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| JP7278273B2 (ja) | 2017-10-18 | 2023-05-19 | ブループリント メディシンズ コーポレイション | アクチビン受容体様キナーゼの阻害剤としての置換ピロロピリジン |
| CN108191874B (zh) * | 2018-01-16 | 2019-11-29 | 成都施贝康生物医药科技有限公司 | 一种C-Kit抑制剂及其应用 |
| JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物 |
| US11603374B2 (en) | 2018-01-18 | 2023-03-14 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| TW201938169A (zh) | 2018-01-18 | 2019-10-01 | 美商亞雷生物製藥股份有限公司 | 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物 |
| CA3096043A1 (en) | 2018-04-03 | 2019-10-10 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
| WO2019201194A1 (zh) * | 2018-04-16 | 2019-10-24 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡咯并三嗪类化合物及其药物组合物及其用途 |
| WO2019165566A1 (es) | 2018-06-22 | 2019-09-06 | Comercializadora Innvento S.A. | Artículo filtrante-absorbente multicapa que comprende una primera capa de un soporte poroso de carbón activado dispuesto sobre un fieltro no tejido de fibras de poliéster, una segunda capa de una película de polímero y una tercera capa de un agente activo; proceso para obtener dicho artículo; y uso del mismo |
| CA3224985A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
| CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| US20220010382A1 (en) | 2018-11-12 | 2022-01-13 | Blueprint Medicines Corporation | Avapritinib resistance of kit mutants |
| CN109232583A (zh) * | 2018-11-29 | 2019-01-18 | 尚科生物医药（上海）有限公司 | 一种6-溴-3H-吡咯并[2,1-f][1,2,4]三嗪-4-酮的制备方法 |
| CN113490666A (zh) | 2018-12-19 | 2021-10-08 | 奥瑞生物药品公司 | 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物 |
| EP3898615A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| CN111410648B (zh) * | 2019-01-07 | 2024-03-29 | 浙江海正药业股份有限公司 | 一种手性c-KIT抑制剂药物关键中间体及其制备方法 |
| CN113966334B (zh) | 2019-04-12 | 2025-01-21 | 缆图药品公司 | 化合物(i)的晶体形式 |
| MA55604B1 (fr) * | 2019-04-12 | 2024-08-30 | Blueprint Medicines Corporation | Dérivés de pyrrolotriazine pour le traitement de maladies liées au kit- and pdgfra |
| AU2020278162A1 (en) * | 2019-05-21 | 2021-11-18 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a BTK inhibitor |
| US20220267334A1 (en) * | 2019-07-09 | 2022-08-25 | Sandoz Ag | Crystalline forms of an orally available, selective kit and pdgfr kinase inhibitor |
| TW202126306A (zh) | 2019-10-04 | 2021-07-16 | 美商纜圖藥品公司 | 嗜酸性球性病症之治療 |
| GB201915447D0 (en) | 2019-10-24 | 2019-12-11 | Johnson Matthey Plc | Polymorphs of avapritinib and methods of preparing the polymorphs |
| EP4054587A1 (en) * | 2019-11-04 | 2022-09-14 | Blueprint Medicines Corporation | Treatment of mast cell diseases and eosinophilic disorders |
| EP4069369A4 (en) | 2019-12-06 | 2024-02-14 | Schrödinger, Inc. | CYCLIC COMPOUNDS AND METHODS OF USE THEREOF |
| CN110938077B (zh) * | 2019-12-25 | 2021-04-27 | 武汉九州钰民医药科技有限公司 | 合成Avapritinib的方法 |
| CN110950872A (zh) * | 2019-12-25 | 2020-04-03 | 武汉九州钰民医药科技有限公司 | 制备靶向抗癌药avapritinib的方法 |
| PH12022551523A1 (en) | 2019-12-27 | 2024-01-29 | SchraDinger Inc | Cyclic compounds and methods of using same |
| WO2021183709A1 (en) | 2020-03-11 | 2021-09-16 | Teva Czech Industries S.R.O | Solid state forms of avapritinib and process for preparation thereof |
| CA3183728A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| EP4168119A1 (en) | 2020-06-17 | 2023-04-26 | Teva Czech Industries s.r.o. | Solid state forms of avapritinib salts |
| TW202212354A (zh) | 2020-08-03 | 2022-04-01 | 美商健生生物科技公司 | 用於病毒治療劑中之多向生物運輸的材料及方法 |
| CN116490507A (zh) | 2020-09-10 | 2023-07-25 | 薛定谔公司 | 用于治疗癌症的杂环包缩合cdc7激酶抑制剂 |
| JP2023546109A (ja) * | 2020-10-14 | 2023-11-01 | ブループリント メディシンズ コーポレイション | Ｋｉｔおよびｐｄｇｆｒａ媒介疾患を処置するための組成物および方法 |
| WO2022081626A1 (en) | 2020-10-14 | 2022-04-21 | Blueprint Medicines Corporation | Compositions and methods for treating kit-and pdgfra-mediated diseases |
| CN112552339A (zh) * | 2020-12-10 | 2021-03-26 | 安徽昊帆生物有限公司 | 一种o-二苯基磷酰羟胺的制备方法 |
| JP2024505890A (ja) | 2021-01-26 | 2024-02-08 | シュレーディンガー， インコーポレイテッド | がん、自己免疫及び炎症性障害の治療に有用な三環式化合物 |
| HU231413B1 (hu) | 2021-02-26 | 2023-08-28 | Egis Gyógyszergyár Zrt. | Eljárás avapritinib és intermedierek előállítására |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| CN113278023B (zh) * | 2021-07-22 | 2021-10-15 | 上海睿跃生物科技有限公司 | 含氮杂环化合物及其制备方法和应用 |
| CN113686987B (zh) * | 2021-08-19 | 2022-04-26 | 海南医学院 | 一种用于检测Avapritinib中间体中对映异构体的方法 |
| IL312506A (en) | 2021-11-08 | 2024-07-01 | Progentos Therapeutics Inc | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| CN119585250A (zh) * | 2022-04-19 | 2025-03-07 | 蓝图药品公司 | Kit抑制剂 |
| US20240382493A1 (en) * | 2023-05-18 | 2024-11-21 | Blueprint Medicines Corporation | Methods for treating systemic mastocytosis and gastrointestinal stromal tumors |
| WO2024249855A1 (en) * | 2023-06-02 | 2024-12-05 | Idrx, Inc. | Combination therapy comprising kit inhibitors for use in the treatment of cancer |
| WO2025059027A1 (en) | 2023-09-11 | 2025-03-20 | Schrödinger, Inc. | Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors |
| WO2025170989A1 (en) | 2024-02-05 | 2025-08-14 | Blueprint Medicines Corporation | High-risk disease features of indolent systemic mastocytosis and methods for treating |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61238784A (ja) | 1985-04-17 | 1986-10-24 | Sumitomo Seiyaku Kk | コハク酸イミド誘導体及びその酸付加塩 |
| WO2000071129A1 (en) * | 1999-05-21 | 2000-11-30 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| AU770600B2 (en) | 1999-10-07 | 2004-02-26 | Amgen, Inc. | Triazine kinase inhibitors |
| US6784603B2 (en) * | 2001-07-20 | 2004-08-31 | Teledyne Lighting And Display Products, Inc. | Fluorescent lighting apparatus |
| SE0102616D0 (sv) * | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| BR0309669A (pt) | 2002-04-23 | 2005-03-01 | Bristol Myers Squibb Co | Compostos de anilina de pirrolo-triazina úteis como inibidores de cinase |
| TW200508224A (en) | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| DE602004029145D1 (de) * | 2003-02-27 | 2010-10-28 | Palau Pharma Sa | Pyrazolopyridin-derivate |
| AU2005249380C1 (en) * | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
| WO2005115397A2 (en) | 2004-04-29 | 2005-12-08 | Pharmix Corporation | Compositions and treatments for modulating kinase and/or hmg-coa reductase |
| US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US20050288290A1 (en) * | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| WO2007056170A2 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| US7348325B2 (en) * | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| KR101452520B1 (ko) * | 2006-01-27 | 2014-10-21 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | 피롤로[3,2-ｃ]피리딘-4-온 2-인돌린온 단백질 키나제 억제제 |
| CN101007814A (zh) * | 2006-01-27 | 2007-08-01 | 上海恒瑞医药有限公司 | 吡咯并六元杂环化合物及其在医药上的用途 |
| PT2041138E (pt) | 2006-07-07 | 2014-10-07 | Bristol Myers Squibb Co | Inibidores de pirrolotriazina quinase |
| KR20100038108A (ko) | 2007-07-25 | 2010-04-12 | 브리스톨-마이어스 스큅 컴퍼니 | 트리아진 키나제 억제제 |
| ES2413806T3 (es) | 2008-03-20 | 2013-07-17 | Amgen Inc. | Moduladores de la aurora cinasa y método de uso |
| KR20100003912A (ko) | 2008-07-02 | 2010-01-12 | 삼성전자주식회사 | 동일 포맷의 미디어 파일 간에 미디어 정보 호환이 가능한미디어 파일을 생성하는 방법 및 장치와 미디어 파일을실행하는 방법 및 장치 |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| CN102573486A (zh) | 2009-06-08 | 2012-07-11 | 加利福尼亚资本权益有限责任公司 | 三嗪衍生物及其治疗应用 |
| TW201105662A (en) | 2009-07-07 | 2011-02-16 | Pathway Therapeutics Ltd | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| CA2789711C (en) | 2010-02-17 | 2014-08-05 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
| WO2012027495A1 (en) | 2010-08-27 | 2012-03-01 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| CN102040494A (zh) | 2010-11-12 | 2011-05-04 | 西北师范大学 | 对氟苯甲醛的制备方法 |
| RU2013127611A (ru) * | 2010-12-23 | 2015-01-27 | Пфайзер Инк. | Модуляторы глюкагонового рецептора |
| BR112015000653A2 (pt) | 2012-07-11 | 2019-11-05 | Blueprint Medicines Corp | compostos inibidores do receptor de fator de crescimento de fibroblasto, sua composição farmacêutica e seus usos |
| JP6318156B2 (ja) | 2012-09-06 | 2018-04-25 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼをモジュレートするための化合物および方法、ならびにその指標 |
| PE20151280A1 (es) | 2012-12-21 | 2015-09-12 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas y sus indicaciones |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| RS57542B1 (sr) | 2013-10-17 | 2018-10-31 | Blueprint Medicines Corp | Kompozicije korisne za lečenje poremećaja povezanih sa kit-om |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| DK3395814T3 (da) | 2013-10-25 | 2022-07-04 | Blueprint Medicines Corp | Hæmmere af fibroblastvækstfaktorreceptoren |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| JP2018521076A (ja) | 2015-07-24 | 2018-08-02 | ブループリント メディシンズ コーポレイション | Ｋｉｔ及びｐｄｇｆｒに関連する疾病を治療するのに有用な化合物 |
| CA2995997A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| TWI787018B (zh) | 2015-11-02 | 2022-12-11 | 美商纜圖藥品公司 | 轉染過程重排之抑制劑 |
| KR20180081790A (ko) | 2015-11-19 | 2018-07-17 | 블루프린트 메디신즈 코포레이션 | Ntrk 관련 장애의 치료에 유용한 화합물 및 조성물 |
| UY37155A (es) | 2016-03-17 | 2017-10-31 | Blueprint Medicines Corp | Inhibidores de ret |
| FI3442977T3 (fi) | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| CN110022900A (zh) | 2016-09-08 | 2019-07-16 | 蓝图药品公司 | 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合 |
| WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| CN109400610A (zh) | 2017-08-18 | 2019-03-01 | 浙江海正药业股份有限公司 | 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途 |
| CN108191874B (zh) | 2018-01-16 | 2019-11-29 | 成都施贝康生物医药科技有限公司 | 一种C-Kit抑制剂及其应用 |
| US20220010382A1 (en) | 2018-11-12 | 2022-01-13 | Blueprint Medicines Corporation | Avapritinib resistance of kit mutants |
| CN113966334B (zh) | 2019-04-12 | 2025-01-21 | 缆图药品公司 | 化合物(i)的晶体形式 |
| CN110950872A (zh) | 2019-12-25 | 2020-04-03 | 武汉九州钰民医药科技有限公司 | 制备靶向抗癌药avapritinib的方法 |
| CN110938077B (zh) | 2019-12-25 | 2021-04-27 | 武汉九州钰民医药科技有限公司 | 合成Avapritinib的方法 |
-
2014
- 2014-10-15 RS RS20180915A patent/RS57542B1/sr unknown
- 2014-10-15 MX MX2016004927A patent/MX365614B/es active IP Right Grant
- 2014-10-15 HU HUE18170264A patent/HUE059041T2/hu unknown
- 2014-10-15 WO PCT/US2014/060746 patent/WO2015057873A1/en not_active Ceased
- 2014-10-15 BR BR112016008541-8A patent/BR112016008541B1/pt active IP Right Grant
- 2014-10-15 DK DK14799576.5T patent/DK3057969T3/en active
- 2014-10-15 HU HUE14799576A patent/HUE039687T2/hu unknown
- 2014-10-15 PT PT147995765T patent/PT3057969T/pt unknown
- 2014-10-15 CN CN201910192873.XA patent/CN110003217B/zh active Active
- 2014-10-15 CA CA2926999A patent/CA2926999C/en active Active
- 2014-10-15 HR HRP20181388TT patent/HRP20181388T1/hr unknown
- 2014-10-15 PL PL18170264.8T patent/PL3409674T3/pl unknown
- 2014-10-15 JP JP2016523939A patent/JP6446040B2/ja active Active
- 2014-10-15 PT PT181702648T patent/PT3409674T/pt unknown
- 2014-10-15 RU RU2016118768A patent/RU2706235C2/ru active
- 2014-10-15 US US14/515,327 patent/US9200002B2/en active Active
- 2014-10-15 CN CN201480056950.4A patent/CN105658652B/zh active Active
- 2014-10-15 PL PL14799576T patent/PL3057969T3/pl unknown
- 2014-10-15 SI SI201430841T patent/SI3057969T1/sl unknown
- 2014-10-15 SG SG11201602937UA patent/SG11201602937UA/en unknown
- 2014-10-15 LT LTEP14799576.5T patent/LT3057969T/lt unknown
- 2014-10-15 ES ES14799576.5T patent/ES2683127T3/es active Active
- 2014-10-15 EP EP14799576.5A patent/EP3057969B1/en active Active
- 2014-10-15 ES ES18170264T patent/ES2923888T3/es active Active
- 2014-10-15 AU AU2014337314A patent/AU2014337314B2/en active Active
- 2014-10-15 EP EP18170264.8A patent/EP3409674B1/en active Active
- 2014-10-15 KR KR1020167012391A patent/KR102378689B1/ko active Active
- 2014-10-16 UY UY0001035787A patent/UY35787A/es active IP Right Grant
- 2014-10-16 SM SM20180448T patent/SMT201800448T1/it unknown
- 2014-10-16 TW TW103135888A patent/TWI683814B/zh active
-
2015
- 2015-10-20 US US14/887,614 patent/US9994575B2/en active Active
-
2016
- 2016-03-17 IL IL24467716A patent/IL244677B/en active IP Right Grant
- 2016-03-22 ZA ZA2016/01970A patent/ZA201601970B/en unknown
- 2016-04-05 PH PH12016500611A patent/PH12016500611A1/en unknown
-
2017
- 2017-04-04 US US15/479,145 patent/US9944651B2/en active Active
-
2018
- 2018-05-07 US US15/973,378 patent/US10807985B2/en active Active
- 2018-08-21 CY CY20181100868T patent/CY1121182T1/el unknown
- 2018-11-30 JP JP2018224481A patent/JP6782756B2/ja active Active
-
2020
- 2020-10-14 US US17/070,556 patent/US20210284645A1/en not_active Abandoned
-
2021
- 2021-03-03 NL NL301094C patent/NL301094I2/nl unknown
- 2021-03-03 HU HUS2100006C patent/HUS2100006I1/hu unknown
- 2021-03-11 CY CY2021007C patent/CY2021007I1/el unknown
- 2021-03-16 LT LTPA2021003C patent/LTC3057969I2/lt unknown
- 2021-03-18 NO NO2021012C patent/NO2021012I1/no unknown
-
2022
- 2022-11-09 US US17/983,747 patent/US11827642B2/en active Active
-
2023
- 2023-10-23 US US18/382,727 patent/US20240317757A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201601970B (en) | Compositions useful for treating disorders related to kit | |
| ZA201803530B (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| ZA201801881B (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| PL2984166T3 (pl) | Kompozycje do leczenia mpsi | |
| GB201304662D0 (en) | Compositions | |
| IL241078A0 (en) | Synergistic preparations | |
| GB201608461D0 (en) | Compositions | |
| PL3021839T3 (pl) | Kompozycje do leczenia zwłóknienia | |
| IL235317A0 (en) | A compound for the treatment of metabolic disorders | |
| SG10201706960TA (en) | Organic compositions to treat epas1-related diseases | |
| GB201317105D0 (en) | Novel Composition | |
| IL237483A0 (en) | Preparations for the treatment of psoriasis | |
| ZA201505650B (en) | New compositions | |
| GB201320962D0 (en) | Compositions | |
| GB201316463D0 (en) | Novel compositions | |
| GB201319923D0 (en) | Novel composition | |
| IL239899A0 (en) | Preparations of thiazomycin compounds | |
| GB201310513D0 (en) | Novel composition | |
| EP2968550A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | |
| GB201320959D0 (en) | Compositions | |
| GB201316464D0 (en) | Novel compositions | |
| GB201315598D0 (en) | Novel compositions | |
| GB201312224D0 (en) | Compositions | |
| GB201304927D0 (en) | Compositions | |
| GB201306599D0 (en) | Novel composition |